BioSpace News Archive

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company) today announced that it has successfully completed a feasibility study with its OneRF™ ablation system, a developing technology that utilizes existing implanted sEEG diagnostic electrodes for brain tissue lesioning.

Cosette Pharmaceuticals, Inc began shipping Griseofulvin Oral Suspension, 125 mg/5 mL into all channels in the United States.

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced the launch of the organization’s Electronic Health Record (EHR) Study with the first patients consented to participate.

Medikine, Inc., a clinical-stage biopharmaceutical company developing transformative therapeutics for cancer, autoimmune disorders, and infectious diseases using its novel PEPTIKINE™ technology, today announced the appointment of Roland Buelow, Ph.D., to the company’s board of directors.

Shenandoah Biotechnology Inc., a FUJIFILM Irvine Scientific company and leading manufacturer of recombinant proteins, announced it has expanded its CTGrade portfolio of cytokines and growth factors for cell and gene therapies manufactured following cGMP guidelines.

Nykode Therapeutics ASA (OSE: NYKD) today announced that it has entered into a clinical collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), to evaluate Nykode’s wholly-owned lead candidate, VB10.16, in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase 1/2a trial in patients with HPV16-positive head and neck cancer.

Matterworks, Inc., developers of the world’s most powerful AI platform for modeling real-time biology to accelerate the discovery, development, and manufacturing of life sciences technologies, including biologics and gene therapies, announces CEO appointment and updates to its Board of Directors.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the closing of an underwritten public offering with gross proceeds to the Company of approximately $8.0 million, before deducting underwriting discounts and other expenses payable by the Company.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has been invited to present data on the combination of INB03™ and trastuzumab-deruxtecan (TDxd) for treatment of HER2 positive breast cancer.